The broad, long-term objective is to reduce morbidity and mortality caused by tumors occurring in the HNPCC syndrome. The first task is to define the natural history of HNPCC (e.g. age-dependent risk, spectrum of affected organs, clinical behavior) and the effect of predictive testing on clinical screening and preventive measures. This can be done by determining who is a carrier and who is not among as many as 288 affected and 1169 unaffected at-risk members of 81 previously diagnosed HNPCC families. The frequency of HNPCC will be determined by studying one-fourth of all colorectal carcinomas and adenomas removed in Finland. These will be screened for the replication error (RER) phenomenon that is indicative of, but not specific for, HNPCC. Individuals with RER-positive tumors will be screened for HNPCC mutations. This study will comprise some 2500 individuals annually. As there are almost no established procedures for the handling of data regarding individual susceptibility to a common, adult-onset cancer, the ethical and social aspects of this experiment in predictive testing will be researched by means of repeated individual counseling and evaluation, as well as by attempting to inform the medical profession, to educate the public, and to provide expertise to lawmakers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
7U01CA067941-04
Application #
6135464
Study Section
Metabolic Pathology Study Section (MEP)
Program Officer
Seminara, Daniela
Project Start
1996-03-15
Project End
2000-03-31
Budget Start
1999-07-01
Budget End
2000-03-31
Support Year
4
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Ohio State University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Le, Dung T; Durham, Jennifer N; Smith, Kellie N et al. (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357:409-413
Haraldsdottir, Sigurdis; Hampel, Heather; Wu, Christina et al. (2016) Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses. Genet Med 18:863-8
Le, Dung T; Uram, Jennifer N; Wang, Hao et al. (2015) PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 372:2509-20
Pasche, Boris; Pennison, Michael J; Jimenez, Hugo et al. (2014) TGFBR1 and cancer susceptibility. Trans Am Clin Climatol Assoc 125:300-12
Haraldsdottir, Sigurdis; Hampel, Heather; Tomsic, Jerneja et al. (2014) Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. Gastroenterology 147:1308-1316.e1
Hampel, Heather; de la Chapelle, Albert (2013) How do we approach the goal of identifying everybody with Lynch syndrome? Fam Cancer 12:313-7
Tomsic, J; Senter, L; Liyanarachchi, S et al. (2013) Recurrent and founder mutations in the PMS2 gene. Clin Genet 83:238-43
Tomsic, Jerneja; Liyanarachchi, Sandya; Hampel, Heather et al. (2012) An American founder mutation in MLH1. Int J Cancer 130:2088-95
Tuupanen, Sari; Yan, Jian; Turunen, Mikko et al. (2012) Characterization of the colorectal cancer-associated enhancer MYC-335 at 8q24: the role of rs67491583. Cancer Genet 205:25-33
Win, Aung Ko; Walters, Rhiannon J; Buchanan, Daniel D et al. (2012) Cancer risks for relatives of patients with serrated polyposis. Am J Gastroenterol 107:770-8

Showing the most recent 10 out of 86 publications